Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Miriam Lieberman

Procedural Dermatology New York, NY Medical Doctor

NPI 1861889552 CMS profile 7223527

150 W 55Th St, New York, NY 10019

Open in the dashboard

General payments

$3,601

170 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miriam Lieberman of New York, NY is reported in the CMS Open Payments database as having received $3,601 across 170 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,373 56
2024 General $772 39
2023 General $803 51
2022 General $170 12
2021 General $70 4
2019 General $413 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miriam Lieberman
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Miriam Lieberman were reported at $1,373. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Miriam Lieberman Procedural Dermatology median Middle half National median
2019 $413 $454 $152–$1,260 $163
2020 $0 $243 $90–$835 $114
2021 $70 $337 $102–$1,128 $132
2022 $170 $443 $119–$1,654 $149
2023 $803 $583 $137–$1,838 $160
2024 $772 $611 $132–$1,835 $164
2025 $1,373 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $808 58 payments
  2. Genentech USA, Inc. $653 26 payments
  3. Novartis Pharmaceuticals Corporation $491 26 payments
  4. Amgen Inc. $320 14 payments
  5. Genzyme Corporation $260 3 payments
  6. Sun Pharmaceutical Industries Inc. $144 5 payments
  7. E.R. Squibb & Sons, L.L.C. $135 6 payments
  8. Lilly USA, LLC $102 4 payments
  9. Arcutis Biotherapeutics, Inc. $88 4 payments
  10. Pfizer Inc. $84 4 payments
  11. Other $517 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,601 170 payments
Products named General payments · program years 2019–2025
  1. COSENTYX $466 24 payments
  2. SKYRIZI $436 33 payments
  3. Otezla $320 14 payments
  4. RINVOQ $277 20 payments
  5. DUPIXENT $206 5 payments
  6. VENCLEXTA $183 7 payments
  7. POLIVY $178 8 payments
  8. Winlevi $144 5 payments
  9. SOTYKTU $135 6 payments
  10. CEREZYME $125 1 payment
  11. Other $1,267 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

453

Median for Dermatology: 534

Drug cost

$123,162

Median for Dermatology: $67,151

Branded share of claims

11.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 19 $91,453
Zoryve Roflumilast Brand 21 $20,950
Calcipotriene Generic 12 $1,730
Metronidazole Generic 22 $1,728
Ketoconazole Generic 67 $1,185
Mometasone Furoate Generic 48 $1,009
Fluocinolone Acetonide Generic 26 $843
Clobetasol Propionate Generic 19 $756
Clindamycin Phosphate Generic 19 $750
Ciclopirox Generic 17 $646

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $154
$154 19 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $139
$139 — —
RINVOQ
  • AbbVie, Inc. $116
$116 — —
SKYRIZI
  • AbbVie, Inc. $78
$78 — —
TREMFYA
  • Janssen Biotech, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record